Get weekly updates on this stock
ME The analyst suggests Medifast for its consistent revenue growth (50% annual rate), recurring subscription model, and aggressive international…
The analyst suggests Medifast for its consistent revenue growth (50% annual rate), recurring subscription model, and aggressive international expansion. The company has a strong history of returning cash to investors and has significantly increased its dividend.
The analyst suggests Medifast for its consistent revenue growth (50% annual rate), recurring subscription model, and aggressive international expansion. The company has a strong history of returning cash to investors and has significantly increased its dividend.
“Healthcare is one of my favorite long-term industries and Medifast has proven it with a 343% increase in its dividend over the last five years.”
A named stock, a clear buy or sell stance, and real reasoning. Passing mentions and hype are filtered out.
Each channel counts once per stock, so a single loud voice can't skew the ranking.
We weigh how many creators agree, how convinced they are, and how recent each call is.
1 finance YouTubers analysed Medifast with qualified reasoning — consensus: Buy, average analysis quality 78/100. This is not financial advice; review the individual analyses and sources above.
Among the channels covering Medifast, 1 are buying and 0 are selling or avoiding — overall Buy.
Only qualified analyses count: a clear buy/sell stance on Medifast with real reasoning (valuation, fundamentals, a catalyst or a chart setup). Passing mentions are excluded.